First Time Loading...

Transgene SA
PAR:TNG

Watchlist Manager
Transgene SA Logo
Transgene SA
PAR:TNG
Watchlist
Price: 1.22 EUR -1.61% Market Closed
Updated: May 3, 2024

Intrinsic Value

TNG's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Transgene SA is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of immunotherapies for the treatment of cancer and infectious diseases. [ Read More ]

The intrinsic value of one TNG stock under the Base Case scenario is 4.41 EUR. Compared to the current market price of 1.22 EUR, Transgene SA is Undervalued by 72%.

Key Points:
TNG Intrinsic Value
Base Case
4.41 EUR
Undervaluation 72%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Transgene SA

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling TNG stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Transgene SA

Provide an overview of the primary business activities
of Transgene SA.

What unique competitive advantages
does Transgene SA hold over its rivals?

What risks and challenges
does Transgene SA face in the near future?

Summarize the latest earnings call
of Transgene SA.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Transgene SA.

Provide P/S
for Transgene SA.

Provide P/E
for Transgene SA.

Provide P/OCF
for Transgene SA.

Provide P/FCFE
for Transgene SA.

Provide P/B
for Transgene SA.

Provide EV/S
for Transgene SA.

Provide EV/GP
for Transgene SA.

Provide EV/EBITDA
for Transgene SA.

Provide EV/EBIT
for Transgene SA.

Provide EV/OCF
for Transgene SA.

Provide EV/FCFF
for Transgene SA.

Provide EV/IC
for Transgene SA.

Show me price targets
for Transgene SA made by professional analysts.

What are the Revenue projections
for Transgene SA?

How accurate were the past Revenue estimates
for Transgene SA?

What are the Net Income projections
for Transgene SA?

How accurate were the past Net Income estimates
for Transgene SA?

What are the EPS projections
for Transgene SA?

How accurate were the past EPS estimates
for Transgene SA?

What are the EBIT projections
for Transgene SA?

How accurate were the past EBIT estimates
for Transgene SA?

Compare the revenue forecasts
for Transgene SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Transgene SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Transgene SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Transgene SA compared to its peers.

Compare the P/E ratios
of Transgene SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Transgene SA with its peers.

Analyze the financial leverage
of Transgene SA compared to its main competitors.

Show all profitability ratios
for Transgene SA.

Provide ROE
for Transgene SA.

Provide ROA
for Transgene SA.

Provide ROIC
for Transgene SA.

Provide ROCE
for Transgene SA.

Provide Gross Margin
for Transgene SA.

Provide Operating Margin
for Transgene SA.

Provide Net Margin
for Transgene SA.

Provide FCF Margin
for Transgene SA.

Show all solvency ratios
for Transgene SA.

Provide D/E Ratio
for Transgene SA.

Provide D/A Ratio
for Transgene SA.

Provide Interest Coverage Ratio
for Transgene SA.

Provide Altman Z-Score Ratio
for Transgene SA.

Provide Quick Ratio
for Transgene SA.

Provide Current Ratio
for Transgene SA.

Provide Cash Ratio
for Transgene SA.

What is the historical Revenue growth
over the last 5 years for Transgene SA?

What is the historical Net Income growth
over the last 5 years for Transgene SA?

What is the current Free Cash Flow
of Transgene SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Transgene SA.

Financials

Balance Sheet Decomposition
Transgene SA

Current Assets 18m
Cash & Short-Term Investments 15.7m
Receivables 778k
Other Current Assets 1.5m
Non-Current Assets 27.2m
Long-Term Investments 1.3m
PP&E 12.3m
Intangibles 80k
Other Non-Current Assets 13.5m
Current Liabilities 10m
Accounts Payable 4.5m
Other Current Liabilities 5.5m
Non-Current Liabilities 19.6m
Long-Term Debt 16m
Other Non-Current Liabilities 3.6m
Efficiency

Earnings Waterfall
Transgene SA

Revenue
7.6m EUR
Operating Expenses
-37.7m EUR
Operating Income
-30m EUR
Other Expenses
7.7m EUR
Net Income
-22.3m EUR

Free Cash Flow Analysis
Transgene SA

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

TNG Profitability Score
Profitability Due Diligence

Transgene SA's profitability score is 17/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Negative 3-Years Revenue Growth
Negative 1-Year Revenue Growth
Declining ROE
17/100
Profitability
Score

Transgene SA's profitability score is 17/100. The higher the profitability score, the more profitable the company is.

TNG Solvency Score
Solvency Due Diligence

Transgene SA's solvency score is 44/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Positive Net Debt
Average D/E
44/100
Solvency
Score

Transgene SA's solvency score is 44/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

TNG Price Targets Summary
Transgene SA

Wall Street analysts forecast TNG stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TNG is 4.54 EUR with a low forecast of 3.54 EUR and a high forecast of 5.67 EUR.

Lowest
Price Target
3.54 EUR
190% Upside
Average
Price Target
4.54 EUR
272% Upside
Highest
Price Target
5.67 EUR
365% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

TNG Price
Transgene SA

1M 1M
+8%
6M 6M
-19%
1Y 1Y
-33%
3Y 3Y
-52%
5Y 5Y
-61%
10Y 10Y
-86%
Annual Price Range
1.22
52w Low
1.03
52w High
2.22
Price Metrics
Average Annual Return -6.51%
Standard Deviation of Annual Returns 43.9%
Max Drawdown -73%
Shares Statistics
Market Capitalization 122.7m EUR
Shares Outstanding 100 566 564
Percentage of Shares Shorted
N/A

TNG Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Transgene SA Logo
Transgene SA

Country

France

Industry

Biotechnology

Market Cap

122.7m EUR

Dividend Yield

0%

Description

Transgene SA is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of immunotherapies for the treatment of cancer and infectious diseases. The company is headquartered in Illkirch-Graffenstaden, Grand Est and currently employs 167 full-time employees. The firm designs and develops immunotherapy products to treat cancer and infectious diseases. These products use viral vectors to directly or indirectly destroy diseased cells. The firm has approximately three products in clinical development: two immunotherapy products for cancer treatment and an anti-infective immunotherapy product for chronic hepatitis B. The firm also has various other programs based on its viral vector technology in research or in pre-clinical or clinical development. The firm's activities are focused on human health and, in particular, the research and development of immunotherapy products, including therapeutic vaccines and oncolytic viruses in the field of cancer and infectious diseases. The firm's principal products include TG4010 (MVA-MUC1-IL2), Pexa-Vec (VV-TK-GM-CSF), TG6002 (VV-TK-RR-FCU1), TG1050 (Ad5-HBV) and TG4001 (MVA-HPV-IL2).

Contact

GRAND EST
Illkirch-Graffenstaden
400 Boulevard Gonthier d'Andernach, Parc d'Innovation - CS80166
+33388279100.0
https://www.transgene.fr

IPO

1998-03-25

Employees

167

Officers

CEO & Chairman of the Board
Dr. Alessandro Riva M.D.
Chief Financial Officer
Ms. Lucie Larguier
Executive VP & Chief Scientific Officer
Dr. Eric Quemeneur Ph.D., Pharm.D.
VP, General Counsel & Corporate Secretary
Mr. John Felitti J.D., LLM
Chief Human Resources Officer
Ms. Christelle Schwoerer
VP of Medical Affairs & Chief Medical Officer
Dr. Maud Brandely-Talbot M.D., Ph.D.
Show More
VP & Chief Business Officer
Mr. James Wentworth M.B.A., Ph.D.
VP & Director of Human Resources
Ms. Gaelle Stadtler
Project Leader of Personalized Cancer Vaccines
Kaidre Bendjama
Director of Investor Relations
Ms. Elisabetta Castelli Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one TNG stock?

The intrinsic value of one TNG stock under the Base Case scenario is 4.41 EUR.

Is TNG stock undervalued or overvalued?

Compared to the current market price of 1.22 EUR, Transgene SA is Undervalued by 72%.